Cetrorelix: complete guide

Cetrorelix is a GnRH antagonist peptide approved as Cetrotide, and this guide covers its structure, labeled use, key trials, side effects and regulatory status as of November 17, 2026.

Complete guide6 min read

Key takeaway

Cetrorelix is a GnRH antagonist made of ten amino acids, with the formula C70H92ClN17O14 and a molecular weight of 1431.0 g/mol. FDA approved Cetrotide on August 11, 2000. Its only labeled use is to inhibit premature LH surges in women undergoing controlled ovarian stimulation. The label carries no boxed warning.

At a glance

Article typeComplete guide
Regulatory statusFDA-approved“Cetrotide is an FDA-approved prescription drug, and generic versions are listed on DailyMed.” (this article)
ClassReproductive hormones
Body systemsReproductive system
Studies cited5 in this article · 5 across 1 article on Cetrorelix
Related productsResearch peptide catalog

Cetrorelix is a synthetic peptide that blocks the receptor for gonadotropin-releasing hormone (GnRH). It is an FDA-approved prescription drug sold as Cetrotide and as generic cetrorelix acetate. This guide covers its structure, mechanism, labeled use, key trials, side effects and regulatory status. Every source was checked on November 17, 2026.

Quick answer: Cetrorelix stops natural GnRH from reaching its receptors in the pituitary gland. LH and FSH release then falls, without the initial rise seen with GnRH agonists. Its approved use is limited to assisted reproduction. Trials found pregnancy rates similar to a GnRH agonist and less ovarian hyperstimulation syndrome.

Vitrapep does not sell cetrorelix; this page is a reference summary of published research and regulatory information. It is not medical advice.

What is cetrorelix?

Cetrorelix is a modified copy of GnRH, the brain hormone that controls reproduction. The Cetrotide label calls it “a synthetic decapeptide with gonadotropin-releasing hormone (GnRH) antagonistic activity” (Cetrotide label, 2025). A decapeptide is a chain of ten amino acids. The label states that it differs from natural GnRH at positions 1, 2, 3, 6 and 10.

PubChem gives its sequence as Ac-D-Nal(2)-D-Phe(pCl)-D-Pal(3)-Ser-Tyr-D-Cit-Leu-Arg-Pro-D-Ala-NH2 (PubChem CID 25074887). Several of these building blocks are synthetic, not found in natural GnRH. PubChem also lists SB-75 as a synonym, the code used in early animal studies.

Table 1

Cetrorelix: key facts

Fact Detail
Structure Synthetic decapeptide; GnRH analog with substitutions at positions 1, 2, 3, 6 and 10
Class GnRH antagonist
Molecular formula C70H92ClN17O14
Molecular weight 1431.0 g/mol (PubChem); 1431.06 as anhydrous free base (label)
First FDA approval August 11, 2000 (Cetrotide, NDA 021197)
Brand names Cetrotide; generic cetrorelix acetate from several labelers

Drugs@FDA lists the Cetrotide approval as a new molecular entity (Drugs@FDA). DailyMed also lists cetrorelix acetate products from Apotex, Qilu, Fresenius Kabi, Gland, Meitheal and Akorn (DailyMed search).

How does cetrorelix work?

GnRH from the brain signals the pituitary gland to release two hormones, LH and FSH. The label explains that a rise in estradiol at midcycle boosts GnRH and causes an LH surge. That surge triggers ovulation.

Cetrorelix “competes with natural GnRH for binding to membrane receptors on pituitary cells,” the label says. This controls the release of LH and FSH. The effect on LH is stronger than on FSH. In women, it delays the LH surge and therefore ovulation.

The label adds that an initial release of the body’s own gonadotropins “has not been detected,” which fits an antagonist effect. GnRH agonists such as leuprolide work differently. The effects of cetrorelix on LH and FSH reverse after treatment stops. These label statements describe human pharmacology.

Animal data came first. In a 1990 study in male rats, SB-75 suppressed LH and testosterone for extended periods (Bokser et al., 1990).

What is cetrorelix approved for?

The Cetrotide label gives one indication. It is “indicated for the inhibition of premature LH surges in women undergoing controlled ovarian stimulation.” Controlled ovarian stimulation is part of fertility treatment such as in vitro fertilization. A premature LH surge can trigger ovulation too early in that process.

The label warns that Cetrotide “should be prescribed by physicians who are experienced in fertility treatment.” It also states that pregnancy must be excluded before treatment starts. Cetrorelix has been studied for other conditions, covered below, but none is a labeled use.

What did the key trials show?

The label summarizes five clinical trials, two phase 2 and three phase 3, with 732 patients. Across the phase 3 studies, LH surges occurred in 0.0% to 1.9% of patients. Clinical pregnancy rates per attempt ranged from 19.8% to 22.6%. All trial data below are from humans.

European phase 3 trial (2000). This prospective, randomized study compared cetrorelix with the GnRH agonist buserelin (Albano et al., 2000). It enrolled 188 women in the cetrorelix group and 85 in the buserelin group. An LH and progesterone rise occurred in 1.6% of the cetrorelix group, 3 of 188 women. The authors reported “similar results” for fertilization, cleavage and pregnancy rates.

A report on the same groups looked at ovarian hyperstimulation syndrome (OHSS), a serious overreaction of the ovaries (Ludwig et al., 2000). Moderate to severe OHSS occurred in 1.1% with cetrorelix and 6.5% with buserelin (p=0.03). Pregnancy rates were 22% and 26%, not significantly different.

French multicenter trial (2000). This randomized study compared cetrorelix in 115 women with the agonist triptorelin in 39 women (Olivennes et al., 2000). The authors wrote, “No LH surge occurred after cetrorelix administration.” The cetrorelix group had fewer eggs and embryos, but pregnancy rates did not differ significantly.

Class-level review (2016). A Cochrane review pooled 73 randomized trials with 12,212 participants comparing GnRH antagonists with a long agonist approach (Al-Inany et al., 2016). Live birth showed no conclusive difference (odds ratio 1.02, 95% CI 0.85 to 1.23). Antagonists were linked to less OHSS of any grade (odds ratio 0.61, 95% CI 0.51 to 0.72). The authors rated the evidence moderate quality.

We found no NCT numbers for these early trials.

What side effects does the label list?

The Cetrotide label has no boxed warning. Its safety data cover 949 patients in clinical studies. Events reported in at least 1% of patients, without regard to cause, were OHSS (3.5%), nausea (1.3%) and headache (1.1%).

The label also reports local site reactions, such as redness, bruising, itching and swelling. It says these were usually “of a transient nature, mild intensity and short duration.” After approval, reports included mild to moderate OHSS and hypersensitivity reactions, including anaphylactoid reactions.

Contraindications include hypersensitivity to cetrorelix, extrinsic peptide hormones, mannitol, GnRH or GnRH analogs. Known or suspected pregnancy, lactation and severe kidney impairment are also listed.

What is cetrorelix’s regulatory status, and is it used in research?

Prescription drug. Cetrotide is an FDA-approved prescription drug, and generic versions are listed on DailyMed. In our search of FDA pages, we found no drug safety communication specific to cetrorelix. Its hypersensitivity reports appear in the label itself.

Sport. WADA’s 2026 Prohibited List does not name cetrorelix. Its section S2.2.1 covers “testosterone-stimulating peptides in males.” That section names GnRH and “its agonist analogues,” along with chorionic gonadotrophin, LH and kisspeptin. Athletes should check with their anti-doping organization. Our guide to peptides on the 2026 WADA list covers the sections.

Research. ClinicalTrials.gov lists 140 studies with cetrorelix as an intervention (ClinicalTrials.gov). Most concern infertility treatment. Others include phase 3 trials in benign prostatic hyperplasia, such as NCT00663858, and phase 2 trials in endometriosis and rheumatoid arthritis. None of these uses is approved. Registry entries record study status, not proof of benefit.

For related compounds, see our guides to ganirelix, degarelix and gonadorelin, and our overview of peptide hormones.

Frequently asked questions about cetrorelix

Is cetrorelix a GnRH agonist or antagonist?

It is an antagonist. It blocks GnRH receptors in the pituitary, and the label reports no initial release of gonadotropins.

Is cetrorelix the same as Cetrotide?

Cetrotide is the brand name, approved in 2000. DailyMed also lists generic cetrorelix acetate from several companies.

How is cetrorelix different from ganirelix?

Both are GnRH antagonists with the same labeled purpose. Their structures differ at some positions. Our ganirelix guide covers that drug.

Is cetrorelix banned by WADA?

WADA’s 2026 list does not name it. Section S2.2.1 covers GnRH and its agonist analogues in males. Athletes should check with their anti-doping organization.

What to know now

  • Approval: Cetrotide, approved August 11, 2000; generics are listed on DailyMed.
  • Labeled use: inhibiting premature LH surges during controlled ovarian stimulation.
  • Evidence: human trials found pregnancy rates similar to GnRH agonists and less OHSS.
  • Safety: no boxed warning; OHSS, nausea, headache and local reactions are listed.
  • Sport: not named on WADA’s 2026 list.

What we’re watching

Revisions to the Cetrotide and generic labels on DailyMed. Any update to the Cochrane review of GnRH antagonists. And WADA’s 2027 Prohibited List, which takes effect on January 1, 2027.

More for reproductive system

All 12 compounds for reproductive system

Sources: EMD Serono 2025, CETROTIDE (cetrorelix acetate) prescribing information; U.S. Food and Drug Administration. Drugs@FDA: CETROTIDE, Drugs@FDA: CETROTIDE, NDA 021197; National Center for Biotechnology Information. PubChem compound summary for CID 25074887, PubChem compound summary for CID 25074887, cetrorelix; National Library of Medicine. DailyMed search results: cetrorelix . Retrieved November 17, DailyMed search results: cetrorelix; Albano 2000, Human Reproduction, 15; Ludwig 2000, Archives of Gynecology and Obstetrics, 264; Olivennes 2000, Fertility and Sterility, 73; Al-Inany 2016, Cochrane Database of Systematic Reviews; Bokser 1990, Proceedings of the National Academy of Sciences of the USA, 87; ClinicalTrials.gov. Search results: studies with cetrorelix as an intervention (140 studies). Retrieved November 17, Search results: studies with cetrorelix as an intervention; AEterna Zentaris. Cetrorelix pamoate in patients with symptomatic BPH (ClinicalTrials.gov ID NCT00663858). Retrieved November 17, Cetrorelix pamoate in patients with symptomatic BPH; World Anti-Doping Agency 2025, World Anti-Doping Code International Standard: Prohibited List 2026. All 12 citations

Back to the research library

References

  1. EMD Serono, Inc. (2025). CETROTIDE (cetrorelix acetate) prescribing information (updated September 22, 2025). DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aca7768e-28a7-4027-b1d8-e66247665f79
  2. U.S. Food and Drug Administration. Drugs@FDA: CETROTIDE, NDA 021197. Retrieved November 17, 2026, from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021197
  3. National Center for Biotechnology Information. PubChem compound summary for CID 25074887, cetrorelix. Retrieved November 17, 2026, from https://pubchem.ncbi.nlm.nih.gov/compound/25074887
  4. National Library of Medicine. DailyMed search results: cetrorelix. Retrieved November 17, 2026, from https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=cetrorelix
  5. Albano, C., Felberbaum, R. E., Smitz, J., et al. (2000). Ovarian stimulation with HMG: Results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. Human Reproduction, 15(3), 526–531. PMID 10686191. https://doi.org/10.1093/humrep/15.3.526
  6. Ludwig, M., Felberbaum, R. E., Devroey, P., et al. (2000). Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist Cetrorelix (Cetrotide) in controlled ovarian stimulation for assisted reproduction. Archives of Gynecology and Obstetrics, 264(1), 29–32. PMID 10985616. https://doi.org/10.1007/pl00007479
  7. Olivennes, F., Belaisch-Allart, J., Emperaire, J. C., et al. (2000). Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin). Fertility and Sterility, 73(2), 314–320. PMID 10685535. https://doi.org/10.1016/s0015-0282(99)00524-5
  8. Al-Inany, H. G., Youssef, M. A., Ayeleke, R. O., Brown, J., Lam, W. S., & Broekmans, F. J. (2016). Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database of Systematic Reviews, (4), CD001750. PMID 27126581. https://doi.org/10.1002/14651858.CD001750.pub4
  9. Bokser, L., Bajusz, S., Groot, K., et al. (1990). Prolonged inhibition of luteinizing hormone and testosterone levels in male rats with the luteinizing hormone-releasing hormone antagonist SB-75. Proceedings of the National Academy of Sciences of the USA, 87(18), 7100–7104. PMID 2205853. https://doi.org/10.1073/pnas.87.18.7100
  10. ClinicalTrials.gov. Search results: studies with cetrorelix as an intervention (140 studies). Retrieved November 17, 2026, from https://clinicaltrials.gov/search?intr=cetrorelix
  11. AEterna Zentaris. Cetrorelix pamoate in patients with symptomatic BPH (ClinicalTrials.gov ID NCT00663858). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT00663858
  12. World Anti-Doping Agency. (2025). World Anti-Doping Code International Standard: Prohibited List 2026 (in effect January 1, 2026). https://www.wada-ama.org/en/prohibited-list